. Control of fetal insulin secretion. Am J Physiol Regulatory Integrative Comp Physiol 279: R2179-R2188, 2000.-In this study, we investigated the way in which fetal insulin secretion is influenced by interrelated changes in blood glucose and sympathoadrenal activity. Experiments were conducted in late gestation sheep fetuses prepared with chronic peripheral and adrenal catheters. The fetus mounted a brisk insulin response to hyperglycemia but with only a minimal change in the glucose-to-insulin ratio, indicating a tight coupling between insulin secretion and plasma glucose. In well-oxygenated fetuses, ␣ 2 -adrenergic blockade by idazoxan effected no change in fetal insulin concentration, indicating the absence of a resting sympathetic inhibitory tone for insulin secretion. With hypoxia, fetal norepinephrine (NE) and epinephrine secretion and plasma NE increased markedly; fetal insulin secretion decreased strikingly with the degree of change related to extant plasma glucose concentration. Idazoxan blocked this effect showing the hypoxic inhibition of insulin secretion to be mediated by a specific ␣ 2 -adrenergic mechanism. ␣ 2 -Blockade in the presence of sympathetic activation secondary to hypoxic stress also revealed the presence of a potent ␤-adrenergic stimulatory effect for insulin secretion. However, based on an analysis of data at the completion of the study, this ␤-stimulatory mechanism was seen to be absent in all six fetuses that had been subjected to a prior experimentally induced hypoxic stress but in only one of nine fetuses not subjected to this perturbation. We speculate that severe hypoxic stress in the fetus may, at least in the short term, have a residual effect in suppressing the ␤-adrenergic stimulatory mechanism for insulin secretion. hyperglycemia; catecholamines; idazoxan; propranolol; hypoxia INVESTIGATION OF THE CONTROL of fetal insulin secretion has consisted largely of in vitro rat studies, a modest number of studies in subhuman primates and humans, and in vivo studies in sheep. In vitro studies in the rat have been concerned with the ontogeny of the quantitative insulin response to various secretagogues and specific mechanisms of stimulus-secretion coupling in control of insulin secretion (20, 24, 32) . Of particular interest to our work, adrenergic inhibition of insulin secretion was demonstrated in late gestation fetal rats and in fetal rat pancreatic ␤-cells (16, 22) . In monkeys a minimal fetal insulin response to glucose was found in acute experiments, presumably with sympathoadrenal activation and adrenergic inhibition of insulin secretion (30); we subsequently noted a brisk insulin response to glucose in a more physiological chronic fetal monkey preparation (10). An increasing fetal insulin concentration and insulin-to-glucose ratio (I/G) were found from 17 to 38 wk in human pregnancies (12). In this same study, a lower I/G was seen in smaller fetuses suggesting "pancreatic ␤-cell dysfunction."
INVESTIGATION OF THE CONTROL of fetal insulin secretion has consisted largely of in vitro rat studies, a modest number of studies in subhuman primates and humans, and in vivo studies in sheep. In vitro studies in the rat have been concerned with the ontogeny of the quantitative insulin response to various secretagogues and specific mechanisms of stimulus-secretion coupling in control of insulin secretion (20, 24, 32) . Of particular interest to our work, adrenergic inhibition of insulin secretion was demonstrated in late gestation fetal rats and in fetal rat pancreatic ␤-cells (16, 22) . In monkeys a minimal fetal insulin response to glucose was found in acute experiments, presumably with sympathoadrenal activation and adrenergic inhibition of insulin secretion (30) ; we subsequently noted a brisk insulin response to glucose in a more physiological chronic fetal monkey preparation (10) . An increasing fetal insulin concentration and insulin-to-glucose ratio (I/G) were found from 17 to 38 wk in human pregnancies (12) . In this same study, a lower I/G was seen in smaller fetuses suggesting "pancreatic ␤-cell dysfunction."
Investigations of insulin secretion in fetal sheep have been conducted for the most part in chronic in vivo preparations and most often have been concerned with the insulin response to secretagogues, especially glucose (2, 5, 6, 29) . Studies of the neurohumoral control of insulin secretion in the sheep fetus demonstrated inhibition by epinephrine (Epi) of both basal and glucose-stimulated insulin secretion (14) with the speculation advanced that the previously reported suppression of insulin by fetal hypoxia (34) was secondary to associated increases in sympathoadrenal activity. We confirmed in fetal sheep the inhibitory effect of hypoxemia on the insulin response to hyperglycemia and found a concurrent increase in plasma norepinephrine (NE) and in adrenal secretion of NE and Epi (25) . In that same work, using the ␣-adrenergic blocker phentolamine, we demonstrated this inhibition to be ␣-adrenergic in type. However, as phentolamine is a general ␣-adrenergic blocker, the specific nature of the ␣-inhibitory mechanism involved was not defined. Moreover, conclusions were confounded by the fact that phentolamine directly stimulates insulin secretion (33) .
The present work was designed to test the following hypotheses: 1) in the fetus, insulin secretion is closely matched to extant glucose concentration, 2) resting sympathetic inhibitory tone for insulin secretion is absent in the well-oxygenated fetus, 3) stress-initiated sympathetic activation partially inhibits insulin secretion in the fetus, and 4) this sympathetic inhibition of insulin secretion is mediated by a specific ␣ 2 -adrenergic mechanism.
METHODS
Experimental preparation. Experiments were conducted in mixed-breed ewes with dated singleton pregnancies. Gesta-tional age at the time of the preparative procedure ranged from 119 to 123 days, and at parturition it ranged from 142 to 147 days.
Fetuses were prepared with chronic peripheral and adrenal cannulas as described previously (9) . In brief, under general anesthesia, a femoral arterial catheter was placed in the ewe; femoral arterial and venous catheters were placed in the fetus. A fetal adrenal cannula was established by insertion of a polyvinyl catheter distally in the left renal vein, excision of the left kidney, and placement of a hydraulically activated choker around the renal vein close to its junction with the vena cava. With the choker open and the catheter occluded, adrenal effluent followed its normal path via adrenal veins into the renal vein and then into the vena cava.
With the catheter open and the renal vein occluded by the choker, adrenal outflow was diverted into the catheter.
A minimum of 7 days was allowed for recovery from surgery before experiments were performed. A companion ewe, housed with the experimental animal, was present in the laboratory during all studies. Sample collections were begun a minimum of 60 min after the animals were moved into the laboratory. Maternal inspired O 2 fraction (MFI O 2 ) was adjusted by the insufflation of either 100% O 2 or 10% O 2 plus 2.5% CO 2 , balance nitrogen, into a plastic bag placed over the head of the ewe.
Biochemical methods. Arterial gases were measured by a blood gas analyzer (model 168; Ciba Corning Diagnostics, Medfield, MA) at 37°C; hemoglobin and oxygen saturation were assessed on an OSM 2 Hemoximeter (Radiometer, Copenhagen, Denmark); blood oxygen content was calculated from hemoglobin, PO 2 , and O 2 saturation. Plasma glucose and lactate concentrations were determined on a YSI glucose-lactate analyzer (model 2700 Select; Yellow Springs Instrument, Yellow Springs, OH). Plasma immunoreactive insulin was analyzed by a solid phase 125 I RIA kit (Diagnostics Products, Los Angeles, CA). The intra-and betweenassay coefficients of variation for insulin were Ͻ5.2%.
Catecholamines in plasma were measured by HPLC with electrochemical detection (19, 21) . Adrenal vein and peripheral blood samples were chilled on collection, and the plasma was separated in a refrigerated centrifuge at 4°C within 15 min. Plasma was frozen at Ϫ80°C until assay. For the catecholamine analysis, plasma samples were mixed with the internal standard dihydroxybenzylamine. The catecholamines were adsorbed onto 50-mg acid-washed aluminum oxide (Woelm Neutral; ICN Nutritional Biochemicals, Cleveland, OH) by mixing with Tris buffer at pH 8.5. The alumina was washed twice with water, and the catecholamines were eluted with 100 l of 0.1 M HClO 4 , using a centrifugal microfilter [model MF-5500, Bioanalytical Systems (BAS), West Lafayette, IN]. The resulting acidic extract was injected into a chromatographic system (BAS 200A), which used an amperometric detector (LC4B, BAS) with a potential of 0.065 V vs. a silver-silver chloride electrode. A proprietary mobile phase (CF-1100) and catecholamine column (MF-6213CL), both from BAS, were utilized at a constant temperature of 30°C. Catecholamine concentrations were determined by peak height determination in relation to the internal standard. The intra-and between-assay coefficients of variation were Ͻ10%. The limits of sensitivity were 20 pg of Epi or NE injected onto the column. Adrenal secretion rates were calculated by subtracting the peripheral arterial plasma concentrations of NE and Epi from those in adrenal venous plasma and multiplying by adrenal plasma flow (9) .
Experimental design. From one to four experiments were conducted in random order in each animal with a minimum of 2 days of rest between experiments, which allowed for measured variables to return to original baseline. Studies were performed at the same clock time to avoid the possible influence of circadian variations. Fetal and maternal heart rate and blood pressure were recorded continuously, except during brief periods of peripheral sampling (transducer, model 1280B; recorder, model 7700; and rate computer, model 8812A; Hewlett-Packard, Waltham, MA). Values for fetal blood gases and lactate, NE and Epi secretion, and plasma NE, glucose, and insulin concentrations were determined at 30-min intervals. Sampling for NE and Epi secretion consisted of three consecutive precisely timed 2-min collections of adrenal venous effluent from which a mean value was derived.
Each study was 6 h in length and followed the same basic format with sampling as above during three 2-h periods or segments. Segment 1 consisted of baseline observations. In segment 2, fetal oxygenation was enhanced by a MFI O 2 of 100% to ensure against fetal hypoxia. During this period either euglycemia (saline infusion) was maintained or hyperglycemia (fetal glucose infusion at 20 mg ⅐ min Ϫ1 ⅐ kg Ϫ1 estimated fetal body wt) was initiated. In segment 3 the fetal glycemic state (euglycemia or hyperglycemia) associated with segment 2 was continued. Additionally, this period was characterized by either continued hyperoxia (MFI O 2 , 100%) or hypoxia (MFI O 2 , 10%), ␣ 2 -adrenergic blockade by idazoxan (1 mg/kg iv; Sigma Chemical, St. Louis, MO) (11) or idazoxan plus ␤-adrenergic blockade by propranolol (0.5 mg/kg iv; Wyeth-Ayerst, Philadelphia, PA), or no autonomic blockade. Efficacy of the propranolol block was tested by observation of the fetal heart rate response to 5 g isoproterenol (Sigma Chemical) before and after propranolol administration and at the conclusion of the experiment.
The overall study included seven separate experimental groups that are defined by the characteristics of the final 2 h of the experiment (segment 3) Data regarding the insulin response to glucose are derived from groups I, III, V, VI, and VII, each of which included a 2-h baseline control period (segment 1) and a 2-h period of enhanced oxygenation and glucose infusion (segment 2). Plasma insulins for these groups are illustrated in Fig. 1 . In segment 2, baseline glucose values increased about 2.5-fold, and baseline insulin values increased by 2.5-to 3-fold. The I/G, 0.59 at baseline and 0.70 in segment 2, were not significantly different. The I/G patterns for segments 1 and 2 are illustrated in detail in Fig. 2 , where the mean I/G is shown for each of the four 30-min samples at baseline and for each of the four measurements during segment 2. The I/G at 60 min of hyperglycemia was higher than all control values, and the 90-min value was higher than that for the 90-min control observation. There was no difference among the hyperglycemic values.
Groups II and III (Tables 3 and 4) were concerned with the assessment of a resting sympathetic inhibitory tone for insulin secretion with euglycemia and hyperglycemia. In both groups, fetal oxygenation was enhanced and well maintained throughout segments 2 and 3. In group II, with no exogenous glucose infusion, plasma glucose was unchanged (from baseline) in segment 2 and slightly decreased in segment 3. In group III, with exogenous glucose infusion, plasma glucose increased (from baseline) about 2.5-fold in segments 2 and 3. There was no change in insulin values (from segment 2) in segment 3 with ␣ 2 -adrenergic block by idazoxan in the presence of either euglycemia (Fig. 3A) or hyperglycemia (Fig. 3B) .
Groups IV and V (Tables 5 and 6 ) addressed the effect on insulin secretion of sympathetic activation by hypoxic stress with euglycemia and hyperglycemia. In both groups, in segment 2 with elevated MFI O 2 , fetal oxygenation was enhanced, whereas in segment 3 with a MFI O 2 of 10% there was a precipitous fall in fetal oxygen values. During hypoxia in both groups, pH and PCO 2 decreased and lactate increased; NE and Epi secretion and plasma NE all increased considerably. In group IV with no exogenous glucose infusion during the hypoxic episode in segment 3, plasma glucose increased about 30%; insulin values decreased from those in segments 1 and 2 by about 50%. In group V with exogenous glucose infusion, plasma glucose increased (from baseline) about 2.5-fold in segments 2 and 3. Insulin values increased almost threefold in segment 2, but during the hypoxic episode in segment 3 decreased Ͼ50% to a value that was not different from that at baseline with euglycemia. The I/G during periods of hypoxic stress were not different from one another in the presence of euglycemia ( Fig. 4A ) and hyperglycemia (Fig. 4B) .
Groups VI and VII (Tables 7 and 8) were concerned with elucidation of ␣-and ␤-adrenergic factors in control of insulin secretion. In both groups, in segment 2 fetal oxygenation was enhanced with elevated MFI O 2 , whereas in segment 3 with MFI O 2 of 10% fetal oxygen values fell precipitously. In both groups, during hypoxia in segment 3, pH and PCO 2 decreased and lactate increased; NE and Epi secretion and plasma NE all Values are means Ϯ SE; n ϭ no. of animals. Secretory (Sec) data are from left fetal adrenal gland. NE, norepinephrine; Epi, epinephrine. Statistics were performed on log transformations of the data. Significant change from baseline value in individual segment: * P Ͻ 0.01. Significant change from preceding value: † P Ͻ 0.05. increased remarkably and to a similar degree. In both groups, with exogenous glucose infusion in segments 2 and 3, plasma glucose increased about 2.5 times over baseline.
In group VI insulin values increased about threefold in segment 2; in segment 3 with hypoxic stress and ␣ 2 -adrenergic blockade by idazoxan insulin levels more than doubled compared with segment 2 (Fig. 5A) . In group VII insulin values increased about 2.5 times in segment 2; in segment 3, with hypoxic stress and ␣ 2 -block by idazoxan and ␤-block by propranolol, insulin levels increased by only about 25% over those in segment 2 (Fig. 5B) .
In group VI, insulin responses in segment 3 (hyperglycemia, hypoxemia, and ␣-blockade) varied markedly among experiments and were seen to fall into lowinsulin (increase Ͻ30%) and high-insulin (increase Ͼ90%) subgroups (Fig. 6 ). The percent changes in individual experiments in the low-insulin subgroup were Ϫ29, 14, 23, 26, 26, 27, and 32 (17 Ϯ 8) and in the high-insulin subgroup were 91, 96, 135, 147, 233, 254, 269, and 283 (189 Ϯ 28). Blood gas, glucose, and catecholamines values were quite similar for the two subgroups (Tables 9 and 10 ). I/G in segment 2 for the low-and high-insulin subgroups (0.59 Ϯ 0.11 and 1.11 Ϯ 0.26, respectively) were not significantly different. However, in segment 3 with hypoxia, the I/G for the low-insulin subgroup (0.81 Ϯ 0.19) was significantly lower than that for the high-insulin subgroup (3.22 Ϯ 1.00; P Ͻ 0.009). The segment 3 insulin levels for the high-insulin subgroup were significantly different from those for group VII (P Ͻ 0.009), whereas the low-insulin subgroup and group VII were not different from one another. Values are means Ϯ SE; n ϭ no. of animals. Statistics were performed on log transformations of the data. Significant change from baseline value in individual segment: * P Ͻ 0.01. 
DISCUSSION
In this study in late gestation sheep fetuses, we examined the response of insulin secretion to increases in plasma glucose and the mechanisms of sympathoadrenal control of insulin release. Extensive in vitro studies in fetal rat tissues have yielded some insight into the ontogeny of stimulus-secretion coupling in control of insulin secretion in that species (20, 24, 32) . However, from such studies little is known of the neurohumoral mechanisms involved other than that Epi blocks the release of insulin by fetal rat ␤-cells (16, 22) . Studies in vivo with intact nervous connections offer evident advantages in the investigation of this area. The sheep fetus generally is well suited to this purpose, allowing the determination in our experimental preparation of adrenal medullary secretion rates of NE and Epi as well as of plasma NE. Given the critical physiological role in sheep of catecholamines of adrenal origin in the inhibition of insulin secretion (3) and in the fetal adaptive response to hypoxia (8) , specific inferences can be drawn regarding the mechanisms of sympathoadrenal influences on insulin release.
Enhanced oxygenation (hyperoxia) with modest increases in fetal PO 2 and Ca O 2 (26) was induced in segment 2 of all experiments to ensure against episodes of hypoxemia as can occur with hyperglycemia (31). This maneuver was effective in that stable fetal oxygen levels were maintained in all except one experiment in which a spontaneous transient hypoxemic episode was seen. NE secretion decreased slightly in groups I, III, and IV with hyperoxia but not in the remaining groups. The shifts in PO 2 in all groups were close to the beginning inflection of the NE secretion-PO 2 curve where some variability animal to animal and thus group to group could reasonably be expected (9) . The absence of significant changes in Epi secretion or plasma NE indicates that physiologically meaningful changes in catecholamines did not occur. In the two groups (II and IV) in which euglycemia was maintained there were no Values are means Ϯ SE; n ϭ no. of animals. Significant change from baseline value in individual segment: * P Ͻ 0.05, † P Ͻ 0.01. Significant change from preceding value: ‡ P Ͻ 0.05, § P Ͻ 0.01. Values are means Ϯ SE; n ϭ no. of animals. Statistics were performed on log transformations of the data. Significant change from baseline value in individual segment: * P Ͻ 0.05, † P Ͻ 0.01. Significant change from preceding value: ‡ P Ͻ 0.01. Fig. 3 . Absence of resting sympathetic tone inhibiting fetal insulin secretion with euglycemia (A, group II) or hyperglycemia (B, group III). In each group, there was a 2-h baseline segment (C), a 2-h segment of enhanced oxygenation with a MFI O 2 of 100% (O), and a 2-h segment with continued enhanced oxygenation plus ␣ 2 -adrenergic blockade by idazoxan (O ϩ I). In group II, euglycemia (EU) was maintained throughout; in group III, hyperglycemia (HG) was induced in segment 2 and maintained in segment 3 by fetal infusion of glucose at 20 mg ⅐ kg Ϫ1 ⅐ min
Ϫ1
. Data represent means Ϯ SE of four 30-min samples during each of three 2-h segments. *P Ͻ 0.01 relative to baseline, control. changes in plasma glucose or insulin in segment 2 compared with segment 1. Group I served as a universal control in that experimental conditions (hyperoxia and hyperglycemia) were unchanged from segment 2 to segment 3. The absence of significant changes in glucose, insulin, or other measured parameters between these two segments indicates stability of the preparation and absence of spurious and thus confounding changes during the final 2 h (segment 3) of the experiments.
Fetal insulin response to glucose. The experimental design provided a large body of data regarding the fetal insulin response to a glucose stimulus. These data were derived from five experimental groups (I, III, V, VI, and VII), each of which included a 2-h baseline control segment and a 2-h segment of maternal oxygen breathing with fetal infusion of glucose.
The capacity of the relatively mature (Ͼ110 days of gestation) sheep fetus to mount a vigorous insulin response to elevations in plasma glucose has been clearly demonstrated (13, 23) . Our study was compatible with this earlier work but yielded new data of interest. Whereas exogenous glucose infusion led to a marked increase in plasma insulin (Fig. 1) , the average I/G was not significantly increased above baseline. Observation of I/G at each 30-min sampling point gives a more dynamic picture of the insulin responses (Fig. 2) . The ratios at 60 and 90 min in segment 2 were modestly higher than equivalent values at the euglycemic baseline, showing a small, temporary overshoot in insulin secretion in response to exogenous glucose. Nevertheless, these overall results are remarkable for the narrow range of I/G over a wide range of glucose concentrations and show clearly a close match between insulin secretion and glucose concentration. Maintenance of stable I/G over a 2-h period suggests considerable insulin secretory capacity, although of course the metabolic clearance of insulin could also be a contributing factor in maintaining plasma insulin levels. There was also no apparent relationship between insulin or I/G and prior hypoxic stress, a point that will be alluded to below. Values are means Ϯ SE; n ϭ no. of animals. Significant change from baseline value in individual segment: * P Ͻ 0.05, † P Ͻ 0.01. Significant change from preceding value: ‡ P Ͻ 0.05, § P Ͻ 0.01. . Plasma glucose levels in segment 3 were 26.6 Ϯ 1.9 and 54.2 Ϯ 2.9 mg/ml in groups IV and V, respectively. Catecholamine values were similar in both groups. Data are presented as means Ϯ SE of four 30-min samples during each of three 2-h segments. *P Ͻ 0.01 relative to preceding values.
Absence of baseline sympathetic tone inhibiting fetal insulin secretion. ␣ 2 -Adrenergic blockade with idazoxan in segment 3 induced no change from segment 2 in insulin levels in the well-oxygenated fetus during periods of euglycemia (group II) or hyperglycemia (group III) (Fig. 3) . With the decrease in glucose in segment 3 in group II, there was an equivalent decrease in plasma insulin maintaining an exact match with segment 2 in the I/G. Given the demonstrated efficacy of idazoxan as an ␣ 2 -blocking agent in group VI, this indicates that resting sympathoadrenal tone does not modify the secretion of insulin by the fetus in the basal state. The marked inhibition of insulin by induced hypoxemia seen in groups IV and V (Table 5 , Fig. 4 ) demonstrated the potential effect of increased sympathetic activity on insulin secretion and supports the concept that this inhibitory system is present but inactive in the resting state. These findings are in keeping with what has been found in adult animals (33) . The suggestion made previously that such a resting inhibitory tone for insulin secretion does exist in fetal sheep (35) is erroneous. That study was based on the use of the general ␣-adrenergic blocking agent phentolamine, which was subsequently shown to have, in addition to its blocking action, a direct stimulatory effect on insulin secretion (33) .
Inhibition of insulin secretion by hypoxic stress in euglycemia and hyperglycemia. Hypoxic stress with its associated adrenergic activation resulted in a marked inhibition of insulin in both euglycemic and hyperglycemic states consistent with our earlier work and that of others (14, 25, 31) . In the presence of euglycemia (group IV), there was an absolute decrease in plasma insulin in the hypoxic period compared with both hyperoxic and baseline segments. With hyperglycemia (group V), the elevated plasma insulin in segment 2 decreased markedly in segment 3 with hypoxia but only to a value that was not different from the euglycemic baseline value. The character of this inhibitory mechanism is demonstrated more clearly by the I/G during the final (hypoxic) segment, which was virtually the same with euglycemia and hyperglycemia (Fig. 4) . The degree of sympathoadrenal stimulation in the two groups was equivalent as indicated by the close similarity of values for NE and Epi secretion and plasma NE. This indicates that within the observed physiological ranges, the inhibitory effect of sympathoadrenal activation is closely dependent on existing glucosemediated insulin secretion.
It has been stated that in the adult ␣ 2 -adrenergic action "inhibits insulin secretion independent of the blood glucose concentration" (36) and furthermore that Fig. 5 . Effect on fetal insulin secretion of combined hypoxia (MFI O 2 10%) with ␣ 2 -adrenergic blockade by idazoxan (H ϩ I) (A, group VI) and combined hypoxia, ␣ 2 -blockade and ␤-adrenergic blockade by propranolol (H ϩ I ϩ P) (B, group VII). In each group there was a 2-h baseline segment (C), a 2-h segment of enhanced oxygenation with an MFI O 2 of 100% (O), and a 2-h segment with perturbations as stated. In the control segments, fetuses were euglycemic (EU); in segments 2 and 3, fetuses were hyperglycemic (HG) secondary to a glucose infusion at 20 mg ⅐ kg Ϫ1 ⅐ min Ϫ1 . Data represent means Ϯ SE of four 30-min samples during each of three 2-h segments. *P Ͻ 0.05 relative to control. ϩP Ͻ 0.05 relative to preceding value. ϩϩP Ͻ 0.01 relative to preceding value. Values are means Ϯ SE; n ϭ no. of animals. Prop, propranolol. Statistics were performed on log transformations of the data. Significant change from baseline value in individual segment: * P Ͻ 0.01. Significant change from preceding value: † P Ͻ 0.01.
Epi and NE completely inhibit the (insulin) secretory response to all physiological stimuli (4) . By contrast, even though this ␣ 2 -inhibitory mechanism is demonstrably potent in the fetal sheep, it does appear to be dependent on the extant glucose concentration and does not result in an absolute cutoff of insulin secretion as in the adult. It is possible that the degree of hypoxiainduced sympathoadrenal activation in our in vivo fetal preparation was less than that attained in studies in adult animals or in vitro with adult ␤-cells (27) . It is also possible that the inhibitory mechanism itself may be immature in the fetus. It has been shown that ␣ 2 -adrenoceptors, rather than being a single entity, are composed of several different proteins encoded by different genes (28) . Moreover, the suggestion has been made that different ␣ 2 -receptor types may be responsible for activating different ones of the diverse intracellular events known to result from ␣ 2 -adrenergic activation in ␤-cells. In keeping with the concept of fetal immaturity, only a single ␣ 2 -adrenoceptor type is present in islets cells of neonatal rats (37) . It may then be true that the complete ␣ 2 -adrenergic inhibitory profile is not fully developed in the sheep fetus.
␣-and ␤-Adrenergic factors in control of insulin secretion. In group VI (Table 7) , idazoxan not only blocked the insulin-inhibiting effect of sympathoadrenal activation during hypoxia but was associated with enhanced insulin secretion. This confirms that the inhibition of insulin secretion by hypoxic stress in the sheep fetus is based on a specific ␣ 2 -adrenergic mechanism. Because experiments referred to above (groups II and III) clearly demonstrated the absence of any agonist effect of idazoxan on insulin, we assumed that the enhancement of insulin secretion was due to the then unopposed action of a stimulatory mechanism. This mechanism must of necessity have been activated by the hypoxic stress because it was not present in the well-oxygenated fetus. This could conceivably have been parasympathetic (vagal) or ␤-adrenergic in nature (36) . The former seems unlikely because vagal activity in adult animals is generally believed to act via the central nervous system to enhance insulin secretion in anticipation of food intake, i.e., the preabsorptive insulin response. As ␤-adrenergic stimulation of Fig. 6 . Low (A) and high (B) fetal insulin response subgroups of group VI secondary to combined hypoxia (MFI O 2 10%) and ␣ 2 -adrenergic blockade by idazoxan (H ϩ I). In each subgroup, there was a 2-h baseline segment (C), a 2-h segment of enhanced oxygenation with MFI O 2 of 100% (O), and a 2-h segment with the perturbation as stated. In the control segment, fetuses were euglycemic (EU); in segments 2 and 3, fetuses were hyperglycemic (HG) secondary to a glucose infusion at 20 mg ⅐ kg Ϫ1 ⅐ min
. Six of seven low-response fetuses had experienced a prior experimental bout of hypoxia; none of the eight high-response fetuses had been subjected to hypoxic episodes. Data represent means Ϯ SE of four 30-min samples during each of three 2-h segments. *P Ͻ 0.01 relative to control. ϩP Ͻ 0.01 relative to preceding value. Hypoxia ϩ Ida insulin secretion has been shown (in adult animals) to be manifest when ␣ 2 -adrenergic inhibition is blocked (27) , this seemed to be the probable explanation for the observed insulin stimulatory phenomenon. This concept was further supported by the earlier demonstration of an active ␤-adrenergic stimulatory mechanism for insulin secretion in the sheep fetus (35) . This hypothesis was tested in experiments (group VII) in which idazoxan was given in combination with the ␤-adrenergic blocker propranolol in hyperglycemic, hypoxic fetuses, and in which stress-initiated sympathoadrenal activation was not different from that in group VI. A small increase in insulin was seen in segment 3, but insulin levels and I/G were much lower than in experiments with idazoxan alone. The hypothesis seems to be supported by these results, although we cannot explain the persistence of this small insulin increase. Absence of chronotropic responses to isoproterenol indicated that the ␤-block was complete. With regard to segment 3 insulin results, based on a "post hoc" analysis, experiments in group VI (hyperglycemia, idazoxan, and hypoxic stress) fell into two apparent subgroups, one in which there was no increase or only a modest fractional increase in insulin levels and one in which insulin levels increased by 90% or more. For purposes of identification, we dubbed these subgroups "low insulin" and "high insulin," respectively (Fig. 6 ). Both increases in insulin and I/G were greater in the high-insulin than in the low-insulin subgroups. There also was a clear difference in these parameters between the high-insulin subgroup and the group VII experiments with combined ␣ 2 -and ␤-blockade. Of significance, increases in insulin values and I/G in the low-insulin subgroup were not different from the group VII experiments with ␤-blockade. This suggests that ␤-adrenergic stimulation of insulin secretion was absent or greatly diminished in the low-insulin subgroup.
This phenomenon could not be explained by any consistent pattern in fetal sex (data not shown), gestational age (data not shown), blood oxygen levels, pH, lactate, and plasma NE, and NE and Epi secretion, characteristic of either the low-insulin or the highinsulin subgroup. We did observe that none of the eight fetuses in the high-insulin subgroup had had a prior experimental hypoxic bout, whereas six of the seven fetuses in the low-insulin subgroup had experienced one or more 2-h hypoxic bouts as part of an experiment performed 3-8 days before. It is even possible that the single fetus in the low-insulin subgroup without a defined prior hypoxic episode may have experienced a period of hypoxia at some time during or after surgical preparation. Indeed, there is a wide range of insulin responses in the high-insulin subgroup, which may reflect variations in prior incidental hypoxic exposure. What is clear is that no fetus having experienced a known hypoxic stress demonstrated a high-insulin response.
Even though our experiments were not designed to test for such "residual effects" of fetal stress, our data do suggest that prior hypoxic stress may have altered (suppressed or partially suppressed) the ␤-adrenergic stimulatory mechanism for insulin secretion. As noted earlier, we found no effect of prior hypoxic exposure on the insulin response to glucose nor on the glucoseinsulin results in any other experiment. This suggests that the apparent phenomenon of residual suppression of ␤-adrenergic stimulation of insulin secretion is a specific effect acting at a point outside the primary glucose stimulus-secretion pathway.
In summary, we have defined aspects of control of insulin secretion in the late-gestation sheep fetus. The fetus mounts a brisk insulin response to exogenous glucose. However, the resultant change in the I/G is minimal, indicating a tight coupling between insulin and glucose that is maintained in the face of continuously elevated glucose with little if any change for a period of at least 2 h. In well-oxygenated fetuses, ␣ 2 -adrenergic blockade effects no change in fetal plasma insulin concentrations, indicating the absence of a resting sympathetic inhibitory tone for insulin secretion. Hypoxic stress acting through an ␣ 2 -adrenergic mechanism induces a marked but incomplete inhibition of insulin secretion, which is quantitatively related to extant glucose concentrations. When ␣ 2 -adrenergic inhibitory activity is blocked, a potent ␤-adrenergic stimulatory mechanism for insulin secretion becomes manifest. Based on an analysis of the data at the completion of the study, there is a strong suggestion that severe hypoxic stress in the fetus may, at least in the short term, have a residual effect in suppressing this ␤-adrenergic stimulatory mechanism.
Perspectives
Clinical studies have indicated that intrauterine events may have residual effects on glucose-insulin metabolism perinatally in the newborn (12) or many years later in the adult (18) . Experimentally, glucose intolerance has been reported in the mature offspring of streptozotocin-diabetic rats (1) . These clinical and experimental phenomena have been associated with small neonatal size. Nutritional deprivation during pregnancy has been suggested as the principal overall causative factor in these residual manifestations of prenatal events (18) . However, a recent study in streptozotocin-diabetic rats found fetal growth restriction to be dependent on attenuated placental circulation, which suggests fetal hypoxia, as well as limited substrate transport, to be of significance in this outcome (7) . We previously postulated that low-weight-for-date births, at times occurring with severe maternal diabetes, may be effected at least in part by hypoxic stress, sympathetic activation, and suppression of fetal insulin secretion with a decrease in the net growth promoting effects of that hormone (25) . In support of this concept, an inverse correlation between birth weight and plasma NE was reported in neonates of diabetic mothers (38) . More recently, an association was found between fetal growth retardation and maternal snoring with presumed sleep apnea (15) . Here, the insult to the fetus would more likely be intermittent hypoxia rather than nutritional deprivation. The present work supports the concept of suppression of fetal insulin secretion by intrauterine events such as hypoxic stress and suggests the possibility that moderately severe hypoxia may have a residual effect in suppressing the ␤-adrenergic stimulatory mechanism for insulin secretion. Such an alteration, if persistent, could exaggerate the insulin-suppressive effects of stress-initiated sympathetic activation throughout life. The recent report of an increased incidence of diabetes in hypertensive patients treated with ␤-blockers lends support to this latter concept (17) . These findings suggest the importance of further studies of fetal hypoxic stress and consequent sympathetic activation on metabolic events in the fetus and as causative factors in the residual effects of pathological events during intrauterine development.
